By understanding the genetic factors that contribute to drug toxicity, pharmacogenomics can be used to develop safer drugs and optimize dosing regimens. This can be achieved through genetic screening of patients before prescribing medications, allowing for the identification of those who may be at higher risk of adverse effects. Additionally, pharmacogenomic data can inform the design of clinical trials, ensuring that genetically diverse populations are adequately represented.
